Unicycive Therapeutics Inc
UNCY4.430USD
-0.220-4.73%
Close 07/18, 16:00（ET）Quotes delayed by 15 min
53.05MMarket Cap
LossP/E TTM
More Details of Unicycive Therapeutics Inc Company
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Company Info
Ticker SymbolUNCY
Company nameUnicycive Therapeutics Inc
IPO dateJun 17, 2021
Founded at2016
CEODr. Shalabh Gupta, M.D.
Number of employees22
Security typeOrdinary Share
Fiscal year-endJun 17
Address4300 El Camino Real, Suite 210
CityLOS ALTOS
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94022
Phone16503840642
Websitehttps://unicycive.com/
Ticker SymbolUNCY
IPO dateJun 17, 2021
Founded at2016
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Dr. Saraswati (Sara) Kenkare-Mitra, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Sandeep (Steve) Laumas, M.D.
Dr. Sandeep (Steve) Laumas, M.D.
Independent Director
Independent Director
10.58K
--
Dr. Pramod Gupta, Ph.D.
Dr. Pramod Gupta, Ph.D.
Executive Vice President - Pharmaceutical and Business Operations
Executive Vice President - Pharmaceutical and Business Operations
4.18K
--
Dr. Shalabh Gupta, M.D.
Dr. Shalabh Gupta, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
--
--
Mr. John Townsend
Mr. John Townsend
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Doug Jermasek
Mr. Doug Jermasek
Executive Vice President - Corporate Strategy
Executive Vice President - Corporate Strategy
--
--
Dr. Gaurav Aggarwal, M.D.
Dr. Gaurav Aggarwal, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
8.90%
Great Point Partners, LLC
8.60%
Octagon Capital Advisors LP
7.83%
Nantahala Capital Management, LLC
7.36%
Gupta (Shalabh K)
4.68%
Other
62.63%
Shareholders
Shareholders
Proportion
Vivo Capital, LLC
8.90%
Great Point Partners, LLC
8.60%
Octagon Capital Advisors LP
7.83%
Nantahala Capital Management, LLC
7.36%
Gupta (Shalabh K)
4.68%
Other
62.63%
Shareholder Types
Shareholders
Proportion
Hedge Fund
34.78%
Venture Capital
12.98%
Individual Investor
4.93%
Investment Advisor/Hedge Fund
1.61%
Investment Advisor
0.12%
Research Firm
0.11%
Other
45.47%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
61
6.96M
54.53%
-647.33K
2025Q1
65
6.78M
64.49%
-1.12M
2024Q4
62
69.04M
66.51%
+542.97K
2024Q3
57
54.12M
55.45%
+17.71M
2024Q2
48
26.33M
50.66%
-3.75M
2024Q1
46
28.58M
99.15%
+4.37M
2023Q4
45
24.82M
96.62%
+1.55M
2023Q3
47
22.73M
96.91%
+9.25M
2023Q2
42
9.36M
61.47%
-512.55K
2023Q1
38
9.94M
65.95%
+1.31M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Vivo Capital, LLC
1.14M
8.9%
+140.00K
+14.04%
Mar 31, 2025
Great Point Partners, LLC
1.10M
8.6%
--
--
Mar 31, 2025
Octagon Capital Advisors LP
1.00M
7.83%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
939.20K
7.36%
-100.00K
-9.62%
Mar 31, 2025
Gupta (Shalabh K)
597.25K
4.68%
-100.00
-0.02%
Apr 30, 2025
Logos Global Management LP
507.89K
3.98%
--
--
Mar 31, 2025
Walleye Capital LLC
409.43K
3.21%
-90.57K
-18.11%
Mar 31, 2025
Rosalind Advisors, Inc.
242.49K
1.9%
+242.49K
--
Apr 30, 2025
SilverArc Capital Management, LLC
241.35K
1.89%
-7.32K
-2.94%
Mar 31, 2025
Acuta Capital Partners, LLC
235.29K
1.84%
+4.99K
+2.17%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
